Fingolimod increases brain-derived neurotrophic factor levels and ameliorates amyloid β-induced memory impairment

被引:96
作者
Fukumoto, Kazuya [1 ]
Mizoguchi, Hiroyuki [1 ]
Takeuchi, Hideyuki [2 ]
Horiuchi, Hiroshi [2 ]
Kawanokuchi, Jun [2 ]
Jin, Shijie [2 ]
Mizuno, Tetsuya [2 ]
Suzumura, Akio [2 ]
机构
[1] Nagoya Univ, Environm Med Res Inst, Futurist Environm Simulat Ctr, Chikusa Ku, Nagoya, Aichi 4648601, Japan
[2] Nagoya Univ, Environm Med Res Inst, Dept Neuroimmunol, Chikusa Ku, Nagoya, Aichi 4648601, Japan
基金
日本学术振兴会;
关键词
Fingolimod; Alzheimer's disease; Amyloid beta; Brain-derived neurotrophic factor; CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; FULL-LENGTH; OXIDATIVE STRESS; RAT HIPPOCAMPUS; MESSENGER-RNA; BDNF LEVELS; FTY720; TRKB; MODEL;
D O I
10.1016/j.bbr.2014.03.046
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Alzheimer's disease is a progressive neurodegenerative disorder. Amyloid beta, a neurotoxic protein, causes disruption of hippocampal synaptic plasticity, and induces cognitive impairment in Alzheimer's disease. We previously. revealed that fingolimod, a new oral immunosuppressant used to treat multiple sclerosis, ameliorates oligomeric amyloid beta-induced neuronal damage via up-regulation of neuronal brain-derived neurotrophic factor (BDNF). Here, we showed that oral administration of fingolimod ameliorated the impairment in object recognition memory and associative learning in mice injected with amyloid beta. This effect was associated with restoration of normal BDNF expression levels in the cerebral cortices and hippocampi, suggesting that neuroprotection was mediated by up-regulation of neuronal BDNF levels. Therefore, fingolimod may provide therapeutic effects in patients with Alzheimer's disease. (C) 2014 Elsevier B.V. All rights reserved.
引用
收藏
页码:88 / 93
页数:6
相关论文
共 50 条
[1]   DESIGN, SYNTHESIS, AND STRUCTURE-ACTIVITY-RELATIONSHIPS OF 2-SUBSTITUTED-2-AMINO-1,3-PROPANEDIOLS - DISCOVERY OF A NOVEL IMMUNOSUPPRESSANT, FTY720 [J].
ADACHI, K ;
KOHARA, T ;
NAKAO, N ;
ARITA, M ;
CHIBA, K ;
MISHINA, T ;
SASAKI, S ;
FUJITA, T .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1995, 5 (08) :853-856
[2]  
Asle-Rousta M, 2013, J MOL NEUROSCI, V4, P1
[3]   The immune modulator FTY720 targets sphingosine 1-phosphate receptors [J].
Brinkmann, V ;
Davis, MD ;
Heise, CE ;
Albert, R ;
Cottens, S ;
Hof, R ;
Bruns, C ;
Prieschl, E ;
Baumruker, T ;
Hiestand, P ;
Foster, CA ;
Zollinger, M ;
Lynch, KR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (24) :21453-21457
[4]   Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology [J].
Brinkmann, Volker .
PHARMACOLOGY & THERAPEUTICS, 2007, 115 (01) :84-105
[5]   Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis [J].
Brinkmann, Volker ;
Billich, Andreas ;
Baumruker, Thomas ;
Heining, Peter ;
Schmouder, Robert ;
Francis, Gordon ;
Aradhye, Shreeram ;
Burtin, Pascale .
NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (11) :883-897
[6]   FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation [J].
Choi, Ji Woong ;
Gardell, Shannon E. ;
Herr, Deron R. ;
Rivera, Richard ;
Lee, Chang-Wook ;
Noguchi, Kyoko ;
Teo, Siew Teng ;
Yung, Yun C. ;
Lu, Melissa ;
Kennedy, Grace ;
Chun, Jerold .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (02) :751-756
[7]   Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis [J].
Chun, Jerold ;
Hartung, Hans-Peter .
CLINICAL NEUROPHARMACOLOGY, 2010, 33 (02) :91-101
[8]   Mechanisms of Fingolimod's Efficacy and Adverse Effects in Multiple Sclerosis [J].
Cohen, Jeffrey A. ;
Chun, Jerold .
ANNALS OF NEUROLOGY, 2011, 69 (05) :759-777
[9]  
Conner JM, 1997, J NEUROSCI, V17, P2295
[10]   Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability [J].
Dahlgren, KN ;
Manelli, AM ;
Stine, WB ;
Baker, LK ;
Krafft, GA ;
LaDu, MJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (35) :32046-32053